Autoimmune Disease Overview

Principles

Definition

Autoimmune disease is a classification of medical conditions and a major field of biomedical research concerned with the study of disorders where the immune system fails to distinguish self from non-self, leading to an erroneous attack on the body's own tissues. This research investigates the underlying immunological mechanisms, genetic and environmental risk factors, and the development of diagnostic and therapeutic strategies for these chronic inflammatory conditions.

Ontological type

Pathophysiology

Therapeutic Approaches

Genetic Susceptibility

Key developments

Key Figures

Mechanistic Pathogenesis Foundations era

Henry G. Kunkel [1], associated with Rockefeller University [3] and Harvard University [4], was a central figure in mechanistic autoimmune pathogenesis during this era. His key contributions included immunological studies concerning the nephritis of systemic lupus erythematosus [5], the identification of DNA and antibodies to DNA in the serum of patients with systemic lupus erythematosus [6], and the prototype of immune complex nephritis in man [7], which tied autoantibody and immune complex mechanisms to organ injury and advanced mechanistic inquiry. Peter H. Schur [2], likewise affiliated with Rockefeller University [3] and Harvard University [4], contributed to these mechanistic insights through the same foundational papers and related serologic findings. His era-wide impact is evidenced by how serologic and immune-complex concepts, including DNA-directed autoantibody responses [6] and related serologic findings [5], helped establish a paradigm in which genetic and thymic susceptibility and emerging cytokine insights were integrated to explain autoimmune pathogenesis.

Targeted Cytokine Therapies era

Marc Feldmann [1], with affiliations to the Institute of Cancer Research [3] and the Weizmann Institute of Science [4], contributed to the era's shift toward targeted cytokine therapies. His key contributions in this era include preclinical demonstration that anti-tumor necrosis factor therapy can ameliorate inflammatory disease, as shown by anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis [9], and pivotal clinical trials of infliximab in rheumatoid arthritis, including infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial [8], and infliximab and methotrexate in the treatment of rheumatoid arthritis [7], underscoring the therapeutic potential of TNF blockade in this era. Frank C. Arnett [2], with affiliations to Baylor College of Medicine [5] and The University of Texas Health Science Center at San Antonio [6], contributed to shaping the diagnostic framework for rheumatoid arthritis in this era. His key contribution in this era is the Revised Criteria for the Classification of Rheumatoid Arthritis [10], which standardized patient classification and trial eligibility, enabling consistent evaluation of targeted therapies.

Precision Immunomodulation Era era

Ronald van Vollenhoven [1] is a leading lupus researcher in the Precision Immunomodulation Era, with active affiliations at Harvard University [3] and Stanford University [4]. His key contributions in this era include the Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus [6], a phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus [7], and Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis [8], underscoring the shift toward mechanism-based therapies and biomarker-guided approaches in precision immunomodulation. Michelle Petri [2] is a prominent figure anchored at Harvard–MIT Division of Health Sciences and Technology [5] and Harvard University [3] in this era. Her contributions include the Derivation and validation of the SLICC criteria [6], the Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomized, placebo-controlled, phase 3 trial [9], and the belimumab phase 3 study [7], illustrating how biomarker-guided, B-cell–targeted strategies advanced precision immunomodulation in this era.